Ashish Kulkarni, University of Massachusetts at Amherst (IMAGE)

University of Massachusetts Amherst

Ashish Kulkarni, University of Massachusetts at Amherst

Caption

By re-programming macrophages by injecting tumors with a drug-plus-antibody supramolecule, Ashish Kulkarni and UMass Amherst, with others, report promising preclinical anti-cancer complementary therapy results.

Credit

UMass Amherst

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.